🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07386626
Recruiting Not applicable

Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection

NCT07386626 · tracked via the Priya Life Science China tracker
Sponsor
Tongji Hospital
Phase
Not applicable
Started
2026-03-18
Last updated
2026-04-08

Condition(s) studied

Lobectomy

Investigational drug(s) / intervention(s)

Tegileridine →Intercostal Nerve BlockSufentanil →

Tegileridine: Administer 0.015 mg/kg (maximum 1mg) of tegileridine intravenously 40 minutes before the end of surgery, followed by the connection of a tegileridine patient-controlled intravenous analgesia (PCIA)

Intercostal Nerve Block: Before closing the chest, the thoracic surgeon injected 3mL of 0.4% ropivacaine into the 4th, 5th, 6th and 7th intercostal spaces through thoracoscopy for intercostal nerve block.

Sufentanil: Administer 0.15 μg/kg (maximum 10 μg) of sufentanil intravenously 40 minutes before the end of surgery, followed by the connection of a sufentanil patient-controlled intravenous analgesia (PCIA)

Study summary

Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age range: 18 to 75 years old; * Patients undergoing elective thoracoscopic lobectomy or segmentectomy; * ASA classification levels I-III; * BMI 18 \~ 30 kg/m2。 * Voluntarily participate and sign an informed consent form. Exclusion Criteria: * Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain; * Pregnant or lactating women; * Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study; * Patients with severe sleep apnea syndrome or acute or severe bronchial asthma; * Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc; * Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tongji hospital Wuhan Hubei Recruiting

More Tongji Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07386626 on ClinicalTrials.gov ↗ ← All trials in China